Table 3B. (B) Validation cohort.
|
Overall survival |
Recurrence-free survival |
|||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| MSI vs APC-mt/MSS | 1.21 (0.63–2.34) | 0.569 | 0.70 (0.32–1.54) | 0.375 |
| APC-wt/MSS/ vs MSI | 2.50 (1.25–4.98) | 0.010* | 3.06 (1.34–6.98) | 0.008* |
| APC-wt/MSS vs APC-mt/MSS | 3.02 (1.67–5.47) | <0.001* | 2.14 (1.10–4.18) | 0.025* |
| Age (Decades) | 1.45 (1.15–1.83) | 0.002* | 1.12 (0.87–1.44) | 0.374 |
| Gender (Female vs Male) | 0.37 (0.22–0.63) | <0.001* | 0.47 (0.26–0.85) | 0.012* |
| Stage II vs I | 0.74 (0.22–2.51) | 0.630 | 2.23 (0.30–16.77) | 0.437 |
| Stage III vs I | 1.17 (0.34–4.06) | 0.809 | 4.21 (0.55–32.46) | 0.167 |
| Stage IV vs I | 4.86 (1.22–19.34) | 0.025* | ||
| Chemotherapy (Yes vs No) | 1.26 (0.68–2.32) | 0.458 | 0.89 (0.43–1.82) | 0.742 |
| Events/N | 65/201 | 49/185 | ||
Abbreviation: CI=confidence interval; HR=hazard ratio; MSI=microsatellite instability; MSS=microsatellite stable. *P<0.05.